Advanced Bispecific Nanobody Targeting PDCD1LG2 and TNFRSF4 for Innovative Colon Cancer Therapy
VHH-P498 is a cutting-edge bispecific antibody fusion construct designed to target both programmed cell death 1 ligand 2 (PDCD1LG2) and TNF receptor superfamily member 4 (TNFRSF4). This fully humanized nanobody-based agent is currently in the Biological Testing stage, demonstrating promising potential for the treatment of colon cancer. By engaging two strategically significant immune modulators, VHH-P498 offers a novel approach to address the complex tumor microenvironment and immune evasion mechanisms characteristic of this malignancy, representing a new frontier in biotherapeutic development.
| Candidate | VHH-P498 |
| Target | programmed cell death 1 ligand 2 (PDCD1LG2) TNF receptor superfamily member 4 (TNFRSF4) |
| Modality | humanized bispecific VHH |
| Indication | Colon Cancer |
Licensing Opportunity
VHH-P498 is available for out-licensing opportunities. Partnerships and collaborations are welcomed to accelerate its development and maximize its impact in the field of colon cancer immunotherapy.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P498 |
Modality
VHH-P498 comprises an innovative bispecific antibody structure: a humanized monoclonal IgG1 antibody against CD134 fused to a humanized nanobody targeting programmed death-ligand 1 at each heavy chain C-terminus, linked via a (G4S)4G flexible linker and expressed in HEK293 cells. The nanobody component endows the molecule with a single-domain antibody's compact size and high stability, offering superior tissue penetration and reduced immunogenicity relative to conventional antibodies. These structural characteristics are particularly advantageous for treating colon cancer, allowing efficient access and retention within solid tumor tissues, thereby potentially enhancing therapeutic efficacy.
Target
PDCD1LG2 and TNFRSF4 represent pivotal immunoregulatory molecules involved in tumor immune escape and T cell regulation. PDCD1LG2 is an immune checkpoint molecule, predominantly expressed on antigen-presenting cells and within the tumor microenvironment, where it modulates T cell activity. TNFRSF4 is a member of the tumor necrosis factor receptor family, highly expressed on activated T cells, and functions to co-stimulate immune activation. Both PDCD1LG2 and TNFRSF4 have been extensively studied as key modulators in colon cancer pathophysiology. Targeting PDCD1LG2 and TNFRSF4 with VHH-P498 has strategic value, as combining checkpoint inhibition with immune co-stimulation may provide synergistic anti-tumor responses, positioning VHH-P498 as a differentiated asset in the immuno-oncology landscape.
Mechanism of Action
VHH-P498 exerts its effects through dual targeting: it engages TNFRSF4 to stimulate T cell co-stimulation and immune activation, while simultaneously binding to PDCD1LG2 to block inhibitory checkpoint signaling within the tumor microenvironment. This dual-modulatory approach amplifies anti-tumor immune responses by both activating effector cells and preventing tumor-mediated immune suppression. Furthermore, the nanobody platform enables modular engineering, supporting future development of advanced derivatives such as antibody-drug conjugates (ADCs) or bispecifics tailored for distinct clinical applications. The innovative design of VHH-P498 underscores its potential for broad immunotherapeutic deployment.
Colon Cancer
Colon cancer is among the most prevalent malignancies worldwide, representing a significant cause of morbidity and mortality. Incidence rates are particularly notable in developed countries, with both environmental and genetic factors contributing to disease onset. The current standard of care encompasses surgical resection, chemotherapy, radiotherapy, and increasingly, biologic agents that modulate specific molecular pathways. However, many patients experience disease recurrence or progression, and existing therapies often fall short in addressing advanced or resistant disease cases. There is a pressing need for novel treatments that effectively target immune escape and enhance anti-tumor immunity. By simultaneously modulating key immune checkpoints and co-stimulatory pathways, VHH-P498 offers a promising therapeutic avenue for patients with colon cancer, aiming to overcome resistance mechanisms and deliver improved clinical outcomes.